Dare Bioscience, Inc. (DARE)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 3.5M 7M 10.5M Q3 '14: 86K Q4 '14: 80K Q1 '15: 33K Q4 '21: 0 Q1 '22: 0 Q2 '22: 10M Q3 '22: 10M Q4 '22: 10M Q1 '23: 10M Q2 '23: 0 Q3 '23: 1M Q4 '23: 2.8M Q1 '24: 2.8M Q2 '24: 2.8M Q3 '24: 1.9M Q4 '25: 1M Q1 '26: 1.2M Q2 '26: 1.4M Q1 '15 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-45M -30M -15M 0 15M 30M 45M Q4 '16: -630.6K Q1 '17: -791K Q2 '17: -902.7K Q3 '17: -2.2M Q4 '17: -11.2M Q1 '18: -18.6M Q2 '18: -21.8M Q3 '18: -23.1M Q4 '18: -16.9M Q1 '19: -12.3M Q2 '19: -12.6M Q3 '19: -13.4M Q4 '19: -14.3M Q1 '20: -15.5M Q2 '20: -18.7M Q3 '20: -22.8M Q4 '20: -27.4M Q1 '21: -30.8M Q2 '21: -32.9M Q3 '21: -38M Q4 '21: -39.1M Q1 '22: -39.8M Q2 '22: -30.2M Q3 '22: -24.7M Q4 '22: -31.4M Q1 '23: -31.4M Q2 '23: -40.7M Q3 '23: -42M Q4 '23: -30.9M Q1 '24: -28.6M Q2 '24: -26.9M Q3 '24: -23.2M Q4 '24: -23.5M Q1 '25: -22M Q2 '25: -18.5M Q3 '25: -17.5M Q4 '25: -13.6M Q1 '26: -12M Q2 '26: -11.1M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-60M -40M -20M 0 20M 40M 60M Q1 '16: -44.7M Q2 '16: -45.7M Q1 '17: -5.6M Q2 '17: -5.7M Q3 '17: -7.3M Q4 '17: -11.5M Q1 '18: -18.9M Q2 '18: -22M Q3 '18: -23M Q4 '18: -16.7M Q1 '19: -12.1M Q2 '19: -12.5M Q3 '19: -13.3M Q4 '19: -14.3M Q1 '20: -15.5M Q2 '20: -18.6M Q3 '20: -22.8M Q4 '20: -27.4M Q1 '21: -30.5M Q2 '21: -32.5M Q3 '21: -37.6M Q4 '21: -38.7M Q1 '22: -39.8M Q2 '22: -30.2M Q3 '22: -24.5M Q4 '22: -30.9M Q1 '23: -30.6M Q2 '23: -39.8M Q3 '23: -41M Q4 '23: -30.2M Q1 '24: -28.9M Q2 '24: -7.2M Q3 '24: -3.6M Q4 '24: -4.1M Q1 '25: -1.7M Q2 '25: -18.6M Q3 '25: -17.5M Q4 '25: -13.4M Q1 '26: -12M Q2 '26: -11M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-45M -30M -15M 0 15M 30M 45M Q3 '16: -8.4M Q4 '16: -372.3K Q1 '17: 12.8M Q2 '17: -350K Q3 '17: -1.7M Q4 '17: -2.5M Q1 '18: -4.6M Q2 '18: -7.2M Q3 '18: -8.5M Q4 '18: -10.3M Q1 '19: -11.5M Q2 '19: -11.8M Q3 '19: -12.2M Q4 '19: -13.3M Q1 '20: -16.6M Q2 '20: -17.7M Q3 '20: -19.8M Q4 '20: -25.2M Q1 '21: -27M Q2 '21: -34.7M Q3 '21: -28M Q4 '21: -28.8M Q1 '22: -32.7M Q2 '22: -29.4M Q3 '22: -22.1M Q4 '22: -18.1M Q1 '23: -21.9M Q2 '23: -20M Q3 '23: -36.6M Q4 '23: -38.9M Q1 '24: -29.6M Q2 '24: -10.1M Q3 '24: -8M Q4 '24: 5.5M Q1 '25: 6.8M Q2 '25: -11.5M Q3 '25: -6M Q4 '25: -9.9M Q1 '26: -9.9M Q2 '26: -11.3M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-45M -30M -15M 0 15M 30M 45M Q4 '13: -16.6M Q1 '14: -15.7M Q2 '14: -14.4M Q3 '14: -16.8M Q4 '14: -19.3M Q1 '15: -23.6M Q2 '15: -27.2M Q3 '15: -29.6M Q4 '15: -32.2M Q1 '16: -37.8M Q2 '16: -17M Q3 '16: -9.1M Q4 '16: -907.3K Q2 '21: -34.7M Q3 '21: -28.1M Q4 '21: -28.8M Q1 '22: -32.7M Q2 '22: -29.4M Q3 '22: -22.2M Q4 '22: -18.2M Q1 '23: -21.9M Q2 '23: -20.1M Q3 '23: -36.6M Q4 '23: -39.5M Q1 '24: -30.2M Q2 '24: -11M Q3 '24: -8.6M Q4 '24: 4.9M Q1 '25: 6.1M Q2 '25: -11.8M Q3 '25: -6.8M Q4 '25: -10.3M Q1 '26: -10.2M Q2 '26: -11.8M Q3 '14 Q4 '15 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 30M 60M 90M Q3 '16: 830.5K Q1 '17: 910K Q2 '17: 910K Q3 '17: 5.6M Q1 '18: 8.7M Q2 '18: 11.4M Q2 '20: 26.7M Q3 '20: 31.6M Q1 '21: 44.5M Q2 '21: 50.4M Q3 '21: 70.8M Q1 '22: 83.9M Q2 '22: 85.4M Q3 '22: 84.8M Q1 '23: 85.5M Q2 '23: 7.2M Q3 '23: 7.6M Q1 '24: 8.4M Q2 '24: 8.5M Q3 '24: 8.5M Q1 '25: 8.8M Q2 '25: 8.9M Q3 '25: 12.8M Q1 '26: 14.5M Q2 '26: 14.9M Q3 '16 Q1 '18 Q1 '21 Q2 '22 Q3 '23 Q1 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q3 '16: -4.87 Q4 '16: -4.65 Q1 '17: -4.43 Q2 '17: -1.01 Q3 '17: -1.32 Q4 '17: 3.45 Q1 '18: 2.84 Q2 '18: 3.07 Q3 '18: 3.17 Q4 '18: -1.68 Q1 '19: -1.07 Q2 '19: -1.04 Q3 '19: -1.01 Q4 '19: -0.97 Q1 '20: -0.88 Q2 '20: -0.86 Q3 '20: -0.90 Q4 '20: -0.91 Q1 '21: -0.89 Q2 '21: -0.80 Q3 '21: -0.74 Q4 '21: -0.70 Q1 '22: -0.64 Q2 '22: -0.46 Q3 '22: -0.36 Q4 '22: -0.37 Q1 '23: -0.36 Q2 '23: -1.58 Q3 '23: -2.59 Q4 '23: -3.10 Q1 '24: -3.82 Q2 '24: -1.08 Q3 '24: -0.54 Q4 '24: -0.48 Q1 '25: -0.17 Q2 '25: -2.14 Q3 '25: -1.87 Q4 '25: -1.25 Q1 '26: -0.96 Q2 '26: -0.71 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.